Nancy Hunter
Family · Post Falls, IDNPI 1538539143
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 268 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 32 manufacturers, the largest accounting for just 15.7% — the pattern of someone who eats at a lot of different presentations. Among family clinicians in ID with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 268 payments — averaging $16.57 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- GSK$696
- AbbVie$623
- Exact Sciences$443
- Amgen$367
- Pfizer$366
- Lilly USA, LLC$321
- plus $2K from 26 others
What the payments were for
- Food & beverage$4,439100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| GSK | 73 | $696 |
| AbbVie | 33 | $623 |
| Exact Sciences | 18 | $443 |
| Amgen | 18 | $367 |
| Pfizer | 21 | $366 |
| Lilly USA, LLC | 20 | $321 |
| Novo Nordisk | 17 | $288 |
| Otsuka America Pharmaceutical, Inc. | 11 | $242 |
| AstraZeneca | 10 | $153 |
| Lundbeck LLC | 5 | $101 |
| Boehringer Ingelheim | 4 | $95 |
| Merck | 4 | $88 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 4 | $74 |
| Insulet Corporation | 3 | $70 |
| Novartis | 2 | $63 |
| Sanofi-aventis U.S. LLC | 4 | $62 |
| Bayer | 3 | $44 |
| E.r. Squibb & Sons, L.L.C. | 2 | $39 |
| Biohaven Pharmaceutical Holding Company Ltd. | 2 | $32 |
| Vertex | 1 | $31 |
| Rhythm Pharmaceuticals, Inc. | 1 | $28 |
| Abbott | 1 | $25 |
| Acadia Pharmaceuticals Inc | 1 | $24 |
| Phathom Pharmaceuticals, Inc. | 2 | $23 |
| Gilead | 1 | $22 |
| Eisai Inc. | 1 | $22 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 1 | $20 |
| Alkermes, Inc. | 1 | $19 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $17 |
| Johnson & Johnson | 1 | $16 |
| Hologic Sales And Service, LLC | 1 | $14 |
| Dexcom, Inc. | 1 | $13 |
How this compares
$4,439 in reported general payments places this provider in the 90th percentile of 809 family providers in Idaho.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 102 | $132,602 |
| JardianceEmpagliflozin | 92 | $111,832 |
| OzempicSemaglutide | 57 | $87,471 |
| TrulicityDulaglutide | 52 | $66,248 |
| FarxigaDapagliflozin Propanediol | 54 | $55,518 |
| RybelsusSemaglutide | 24 | $52,098 |
| RexultiBrexpiprazole | 25 | $38,878 |
| EliquisApixaban | 22 | $35,788 |
| XareltoRivaroxaban | 16 | $20,357 |
| MyrbetriqMirabegron | 19 | $17,879 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 15 | $13,519 |
| Repatha SyringeEvolocumab | 11 | $8,117 |
| GemtesaVibegron | 11 | $7,094 |
| Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog | 11 | $5,419 |
| Buprenorphine-NaloxoneBuprenorphine Hcl/Naloxone Hcl | 25 | $4,765 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic, Rybelsus | $288 | $139,57081 claims |
| GSKTrelegy Ellipta | $696 | $132,602102 claims |
| Boehringer IngelheimJardiance | $95 | $111,83292 claims |
| AstraZenecaFarxiga, Breztri Aerosphere | $153 | $69,03769 claims |
| Lilly USA, LLCTrulicity | $321 | $66,24852 claims |
| Otsuka America Pharmaceutical, Inc.Rexulti | $242 | $38,87825 claims |
| PfizerEliquis | $366 | $35,78822 claims |
| Johnson & JohnsonXarelto | $16 | $20,35716 claims |
| AbbVieSynthroid | $623 | $1,66731 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 809 family providers in Idaho.
Other family in Post Falls
- Bobbi BullockNampa$609K
- Michael ParkerMeridian$69K
- Jessica BraksiekBoise$41K
- Travis BlaserBoise$33K
- Alysha SchlackNampa$23K
- Jennifer WatsonCoeur D Alene$21K
- Amber MasseIdaho Falls$17K
- Brian KittelsonMeridian$16K
- Devon MoserBoise$11K
- Jessicka PricePocatello$11K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.